ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at UBS Group in a research note issued to investors on Friday, Marketbeat.com reports. They presently have a GBX 375 target price on the stock. UBS Group’s price target would suggest a potential upside of 59.03% from the company’s previous close.
Several other research analysts also recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research note on Wednesday, July 30th. Berenberg Bank lowered their target price on shares of ConvaTec Group from GBX 335 to GBX 330 and set a “buy” rating for the company in a research note on Tuesday, August 19th. Royal Bank Of Canada upgraded ConvaTec Group to an “outperform” rating and lowered their target price for the company from GBX 320 to GBX 315 in a report on Thursday, August 21st. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a research report on Wednesday, July 30th. Finally, Peel Hunt reiterated a “buy” rating and set a GBX 280 price target on shares of ConvaTec Group in a report on Tuesday, October 28th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 320.33.
Read Our Latest Research Report on CTEC
ConvaTec Group Stock Performance
Insiders Place Their Bets
In related news, insider Jonny Mason purchased 50,000 shares of the business’s stock in a transaction dated Thursday, August 28th. The stock was acquired at an average price of GBX 235 per share, for a total transaction of £117,500. 0.94% of the stock is owned by corporate insiders.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.
Featured Stories
- Five stocks we like better than ConvaTec Group
- 3 Tickers Leading a Meme Stock Revival
- CrowdStrike Partners With CoreWeave But Investors Sell the News
- Retail Stocks Investing, Explained
- Amprius Technologies Signals Electrifying Growth in 2026
- Health Care Stocks Explained: Why You Might Want to Invest
- Dave Stock: 180% Gain + Q3 Beat = Breakout Setup?
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
